SS Innovations International (NASDAQ: SSII), a developer of advanced surgical robotic technologies, has appointed veteran medical technology finance executive Sarah M. Romano as chief financial officer, effective August 3. The appointment comes as the company accelerates its global expansion and moves closer to U.S. regulatory review for its SSi Mantra robotic surgical platform.
Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised more than $100 million during her career. She joins SS Innovations from Vicarious Surgical, another developer of robotic surgical technologies, where she served as CFO and led financial and operational initiatives to reduce cash burn and strengthen the balance sheet. Her expertise is expected to be instrumental as SS Innovations continues pursuing broader commercialization of its SSi Mantra system and prepares for U.S. Food and Drug Administration review (https://nnw.fm/yY4UM).
The company recently graduated the inaugural class of its SS International Centre for Robotics Surgery (SSICRS) cardiac robotic surgery training program, which welcomed 33 healthcare professionals from seven countries. This initiative underscores SS Innovations’ emphasis on surgeon education alongside technology deployment, a critical factor in the adoption of robotic surgery worldwide. By training surgeons from diverse international backgrounds, the company is building a skilled workforce capable of using its systems in various healthcare settings.
Robotic surgery is rapidly transforming the medical landscape, offering benefits such as reduced recovery times, lower complication rates, and enhanced precision. However, widespread adoption hinges on both regulatory approvals and the availability of trained surgeons. SS Innovations’ dual focus on regulatory progress and education positions it to compete with established players like Intuitive Surgical’s da Vinci system. The appointment of a CFO with a proven track record in capital markets also signals that the company may be preparing to raise additional funds to support its expansion and regulatory activities.
For readers in the Long Beach area and beyond, this development highlights how local companies are driving innovation in healthcare technology. The success of SS Innovations could bring advanced surgical options to nearby hospitals, potentially improving patient outcomes and creating high-skilled jobs in the region. Moreover, the company’s international training program positions it as a global player, which could attract further investment and partnerships to Southern California.
As SS Innovations progresses with its FDA submission and expands its training network, the appointment of Sarah M. Romano is a strategic move to strengthen financial oversight and investor confidence. The company’s ability to navigate regulatory hurdles and scale its operations will be closely watched by industry observers and potential partners.
